2 weeks Ago By Defense World Staff
Envestnet Asset Management Inc. trimmed its position in Inari Medical, Inc. (NASDAQ:NARI – Free Report) by 1.
0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,384 shares of the company’s stock after selling 618 shares during the period. Envestnet Asset Management Inc.
owned about 0.10% of Inari Medical worth $2,980,000 at the end of the most recent reporting period. Several other hedge funds also recently modified their holdings of the company.
Barclays PLC increased its stake in shares of Inari Medical by 9.7% during the 3rd quarter. Barclays PLC now owns 288,079 shares of the company’s stock valued at $11,881,000 after acquiring an additional 25,365 shares during the last quarter.
Franklin Resources Inc. increased its position in Inari Medical by 2.2% during the third quarter.
Franklin Resources Inc. now owns 223,810 shares of the company’s stock worth $9,445,000 after purchasing an additional 4,899 shares during the last quarter. GAMMA Investing LLC raised its stake in Inari Medical by 66.
8% during the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock worth $100,000 after purchasing an additional 786 shares during the period. AMI Asset Management Corp acquired a new position in shares of Inari Medical in the 4th quarter valued at $1,651,000.
Finally, KBC Group NV grew its stake in shares of Inari Medical by 31.5% during the 4th quarter. KBC Group NV now owns 2,333 shares of the company’s stock valued at $119,000 after buying an additional 559 shares during the period.
90.98% of the stock is owned by institutional investors and hedge funds. Inari Medical Price PerformanceShares of Inari Medical stock opened at $79.
97 on Friday. Inari Medical, Inc. has a 1-year low of $37.
23 and a 1-year high of $79.99. The company has a market capitalization of $4.
68 billion, a PE ratio of -59.24 and a beta of 1.02.
The business has a 50-day moving average of $79.97 and a 200-day moving average of $66.80.
Wall Street Analyst Weigh InA number of research analysts recently weighed in on NARI shares. Wells Fargo & Company reiterated an “equal weight” rating and issued a $80.00 target price (up previously from $65.
00) on shares of Inari Medical in a report on Tuesday, January 7th. William Blair restated a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Baird R W downgraded shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 7th.
Robert W. Baird reissued a “neutral” rating and issued a $80.00 target price (down previously from $81.
00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, Canaccord Genuity Group restated a “hold” rating and set a $80.00 target price (up previously from $74.
00) on shares of Inari Medical in a report on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $68.
00.Read Our Latest Analysis on NARIAbout Inari Medical (Free Report)Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Further ReadingFive stocks we like better than Inari MedicalNatural Gas Prices Continue To Rally, These Stocks Should BenefitShort Sellers Gave Up on These 3 Names RecentlyThe Most Important Warren Buffett Stock for Investors: His Own3 Boring Stocks Outperforming the Market This YearLow PE Growth Stocks: Unlocking Investment OpportunitiesIf You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy.
